Age-dependent increase in angiopoietin-like protein 2 accelerates skeletal muscle loss in mice

Skeletal muscle atrophy, or sarcopenia, is commonly observed in older individuals and in those with chronic disease and is associated with decreased quality of life. There is recent medical and broad concern that sarcopenia is rapidly increasing worldwide as populations age. At present, strength training is the only effective intervention for preventing sarcopenia development, but it is not known how this exercise regimen counteracts this condition. Here, we report that expression of the inflammatory mediator angiopoietin-like protein 2 (ANGPTL2) increases in skeletal muscle of aging mice. Moreover, in addition to exhibiting increased inflammation and accumulation of reactive oxygen species (ROS), denervated atrophic skeletal muscles in a mouse model of denervation-induced muscle atrophy had increased ANGPTL2 expression. Interestingly, mice with a skeletal myocyte–specific Angptl2 knockout had attenuated inflammation and ROS accumulation in denervated skeletal muscle, accompanied by increased satellite cell activity and inhibition of muscular atrophy compared with mice harboring wildtype Angptl2. Moreover, consistent with these phenotypes, wildtype mice undergoing exercise training displayed decreased ANGPTL2 expression in skeletal muscle. In conclusion, ANGPTL2 up-regulation in skeletal myocytes accelerates muscle atrophy, and exercise-induced attenuation of ANGPTL2 expression in those tissues may partially explain how exercise training prevents sarcopenia.

Sarcopenia is defined as age-related loss of skeletal muscle mass and strength, a condition that worsens quality of life (1). Sarcopenia is now a medical and social concern because the aging population is increasing worldwide. Sarcopenia also develops in patients with chronic disease, such as diabetes, cardiovascular disease, and cancer, and these pathologies accelerate clinical mortality (2). Therefore, clarification of molecular mechanisms underlying sarcopenia development is important to devise effective therapeutic and/or preventive approaches to treat this condition.
Several lines of evidence support the idea that in skeletal muscle chronic inflammation and reactive oxygen species (ROS) 4 accumulation due to redox imbalance contribute to sarcopenia development (3)(4)(5)(6)(7)(8). Chronic inflammation in aging skeletal muscle is positively correlated with sarcopenia development in humans and mice (3,4). The pro-inflammatory cytokines interleukin-6 (IL-6) and interleukin-1␤ (IL-1␤) both decrease skeletal muscle mass by causing inflammation and subsequently facilitating muscle proteolysis, ROS accumulation, and growth hormone resistance (9 -11). Moreover, excess ROS accumulation causes oxidative damage to skeletal muscles, resulting in loss of myofibers (5)(6)(7)(8). Both inflammation and ROS accumulation inactivate "satellite cells," the precursors of skeletal muscle cells (12,13), thereby accelerating sarcopenia development (14). Currently, strength training exercise, which increases the volume of skeletal muscle myofibers, is the only effective way to prevent sarcopenia development. Recent reports suggest that exercise reduces inflammation (15) and ameliorates ROS accumulation by increasing antioxidant activity (16) and also enhances satellite cell activation (17) in animal models of aging. However, molecular mechanisms underlying these activities remain unclear.
Previous studies reveal that expression and secretion of angiopoietin-like 2 (ANGPTL2) significantly increase in cells stressed by pathophysiological stimuli, such as hypoxia and pressure overload (18,19). ANGPTL2 expression also increases in cells undergoing senescence (20,21), suggesting that ANGPTL2 is a senescence-associated secretory phenotype (SASP) factor. Moreover, excess ANGPTL2 signaling is proinflammatory in pathological states and contributes to development of aging-associated diseases such as obesity, diabetes, atherosclerotic disease, chronic kidney disease, and some cancers (22,23).
Although ANGPTL2 hyperactivation is associated with agerelated diseases, ANGPTL2 function in sarcopenia development remains unknown. Here, we investigated the roles of ANGPTL2 in sarcopenia development using aging mice and denervation-induced muscle atrophy mouse model. We report that ANGPTL2 expression increases in skeletal myocytes of aging mice and that running exercise decreases that expression, suggesting that excess ANGPTL2 signaling in aged skeletal muscular myofibers accelerates sarcopenia development. Moreover, ANGPTL2 deficiency in skeletal myocytes attenuated loss of skeletal muscle by reducing muscular inflammation and ROS accumulation and increasing satellite cell activity. To the best of our knowledge, this is the first report showing that ANGPTL2 signaling may accelerate sarcopenia pathologies.

ANGPTL2 expression increases in skeletal myocytes with age
Because ANGPTL2 expression and its circulating levels are positively correlated with aging (19,23,24), we asked whether ANGPTL2 expression increases in aging skeletal muscles. To do so, we first evaluated age-related changes in skeletal muscles of adult (8-month-old) compared with aging (18-month-old) mice. We observed significantly increased expression of proinflammatory and cellular senescence genes in skeletal muscle of aging relative to adult mice (Fig. 1a). Skeletal muscle mass of aging mice was significantly decreased compared with that seen in adult mice (Fig. 1b). In animal tissues, 4-hydroxynonenal (4-HNE) is a lipid peroxidation product whose formation is closely related to oxidative stress (25). Because of its electrophilic nature, 4-HNE reacts with nucleophilic amino acid residues to form 4-HNE-adducted proteins, which serves as a marker of oxidative stress. We also confirmed increased 4-HNE-adducted protein levels and decreased catalase expression in skeletal muscle of aging relative to adult mice; however, we observed no change in expression of superoxide dismutases (Sods) or glutathione peroxidase 1 (Gpx1) (Fig. 1, c and d). Moreover, expression of genes associated with satellite cell activation, such as Cd34, Pax3, and Pax7, in skeletal muscles was significantly decreased in aging relative to adult mice (Fig. 1, e and g, and Fig. S1, a and b).
We next evaluated ANGPTL2 expression in aging and adult mice. Angptl2 mRNA and protein levels significantly increased in skeletal muscle tissues of aging relative to adult mice (Fig. 1,  f and g). Skeletal muscle tissue is composed not only skeletal myocytes but of various stromal cells, such as endothelial cells, macrophages, and infiltrated blood cells. Thus, to determine which cell type in skeletal muscle predominantly expresses ANGPTL2, we prepared both skeletal myocyte (SMC)-and stromal cell-enriched fractions from skeletal muscle of adult and aging mice (Fig. S2). In adult mice, ANGPTL2 protein levels were comparable in both fractions, but in aging mice, ANGPTL2 protein expression was markedly increased in the SMC fraction relative to the stromal cell fraction (Fig. 1h). These results suggest that ANGPTL2 is predominantly increased in skeletal myocytes of aging mice.

ANGPTL2 suppression in skeletal myocytes decreases inflammation and ROS levels and improves cellular senescence phenotypes
To determine the relationship between Angptl2 expression in skeletal myocytes and age-related changes in skeletal muscle, we generated skeletal myocyte-specific Angptl2 knockout (Angptl2 Flox/Flox ;MCK-Cre) mice. We first confirmed that both Angptl2 mRNA and protein expression were decreased by half in Angptl2 Flox/Flox ;MCK-Cre versus Angptl2 Flox/Flox mice (Fig.  2a) and that expression was specifically decreased in skeletal myocytes (Fig. 2b). Skeletal muscle masses were comparable between Angptl2 Flox/Flox ;MCK-Cre and Angptl2 Flox/Flox mice (Fig. 4a), suggesting that ANGPTL2 deficiency in skeletal myocytes does not alter myogenesis or skeletal muscle homeostasis.
Moreover, expression of pro-inflammatory and cellular senescence genes in skeletal muscle significantly decreased in Angptl2 Flox/Flox ;MCK-Cre relative to Angptl2 Flox/Flox mice (Fig.  2c). In addition, although we observed slightly decreased ROS levels in some low-molecular-weight proteins, there was no significant difference in global ROS levels in young skeletal muscle of either genotype (Fig. 2d). However, catalase activity in skeletal muscle of Angptl2 Flox/Flox ;MCK-Cre mice was significantly higher than that seen in Angptl2 Flox/Flox mice (Fig. 2e).
To further assess the effect of ANGPTL2 suppression on myocytes, we conducted loss-of-function studies by transfecting differentiated mouse C2C12 myoblasts with Angptl2 siRNA or control siRNA. ANGPTL2 protein levels were significantly decreased in Angptl2-knockdown cells and in their culture medium compared with control cells (Fig. 2f and Fig. S3a). Expression levels of p21, p57, and Il-6 and senescence-associated ␤-gal activity were all significantly decreased in Angptl2 knockdown relative to control C2C12 cells (Fig. 2, g and h). Moreover, intracellular ROS levels in Angptl2 knockdown cells were significantly lower than those in control cells, whereas catalase expression and activity were significantly increased in knockdown relative to control cells (Fig. 2, i and j). These results suggest that ANGPTL2 suppression in skeletal myocytes enhances ROS clearance capacity by up-regulating catalase and decreasing inflammation and cellular senescence phenotypes.

ANGPTL2 deficiency in myocytes increases skeletal muscle satellite cell activity
Because inflammation and ROS antagonize development of skeletal muscle satellite cells (26), we evaluated satellite cell activity in skeletal muscle of Angptl2 Flox/Flox ;MCK-Cre and Angptl2 Flox/Flox mice. Expression of genes associated with satellite cell activation in Angptl2 Flox/Flox ;MCK-Cre mice was significantly increased compared with that seen in Angptl2 Flox/Flox mice (Fig. 3a). Moreover, immunofluorescence staining revealed that the number of quiescent satellite cells (marked by CD34 ϩ /PAX7 ϩ expression) did not change; however, the number of activated satellite cells (as marked by CD34 Ϫ /PAX7 ϩ expression) increased in skeletal muscle of Angptl2 Flox/Flox ; ANGPTL2 accelerates skeletal muscle atrophy MCK-Cre relative to Angptl2 Flox/Flox mice ( Fig. 3b and Fig. S3c). Immunoblotting analysis also revealed relatively increased PAX7 protein levels in skeletal muscle of Angptl2 Flox/Flox ;MCK-Cre mice (Fig. 3c). Overall, these results suggest that ANGPTL2 suppression in skeletal myocytes promotes satellite cell activation without any impairing of their self-renewal.

ANGPTL2 deficiency in myocytes prevents skeletal muscle atrophy
Because aging-associated inflammation, ROS accumulation, and satellite cell inactivation all reportedly contribute to sarcopenia (7,27,28), we asked whether ANGPTL2 deficiency in skeletal myocytes would protect skeletal muscles from atrophy. Given that spinal motor neuron loss and reduced numbers of motor units characterize aging and directly induce sarcopenia (29), we established a denervation-induced muscle atrophy mouse model to mimic sarcopenia. As anticipated, we observed a significant decrease in skeletal muscle mass relative to wildtype by 7 days after denervation (Fig. S4).
We also observed relatively increased ANGPTL2 protein expression in skeletal muscle post-denervation (Fig. 4b). To assess the pathophysiological significance of this increase, we performed denervation in Angptl2 Flox/Flox ;MCK-Cre mice. By 14 days after denervation, the reduction in skeletal muscle mass seen in wildtype Angptl2 mice was significantly suppressed in Angptl2 Flox/Flox ;MCK-Cre mice (Fig. 4, c and d). Decreased cellular volume seen on a wildtype Angptl2 background was also significantly suppressed in Angptl2 Flox/Flox ;MCK-Cre mice (Fig.  4, e and f), suggesting overall that ANGPTL2 deficiency in skeletal myocytes prevents development of muscle atrophy.
Angptl2 Flox/Flox ;MCK-Cre mice also showed decreased expression of pro-inflammatory genes in denervated skeletal muscle compared with Angptl2 Flox/Flox mice (Fig. 5a). By 14 days after denervation, ROS accumulation and decreased catalase expression seen in denervated skeletal muscle of mice harboring wildtype Angptl2 were significantly suppressed in Angptl2 Flox/Flox ;MCK-Cre mice (Fig. 5, b and c). Expression levels of genes associated with satellite cell activation and PAX7 protein in skeletal muscle were also significantly increased in Angptl2 Flox/Flox ;MCK-Cre mice compared with mice harboring wildtype Angptl2 (Fig. 5, d and e). These results suggest that ANGPTL2 deficiency in skeletal myocytes blocks muscle atrophy by activating satellite cells and decreasing inflammation and ROS accumulation.

Exercise training suppresses ANGPTL2 expression in skeletal muscle
Because exercise training reportedly prevents sarcopenia development (30), we asked whether exercise altered Angptl2 expression in skeletal muscle. To do so, we exposed wildtype mice to exercise training involving running on a treadmill (see "Experimental procedures"). We first confirmed that after exercise training, expression of pro-inflammatory or cellular senescence genes in skeletal muscles significantly decreased and that of genes associated with satellite cell activation significantly increased (Fig. 6, a and b), as reported previously (15)(16)(17). Moreover, expression of Angptl2 mRNA and protein in skeletal muscle was significantly decreased after exercise training (Fig.  6, c and d).
To further evaluate the effect of exercise training on Angptl2 expression in skeletal myocytes, we used two cellular exercise models in which differentiated C2C12 cells are either subjected to mechanical stretch or treated with AICAR (AMP-activated kinase activator) (31,32), both of which lead to cellular changes associated with exercise training. Angptl2 expression levels in differentiated C2C12 cells significantly decreased after mechanical stretch (Fig. 6e), whereas AICAR treatment of C2C12 cells also significantly decreased expression of Angptl2 mRNA and protein (Fig. 6f).

Discussion
This study reveals that ANGPTL2 expression in skeletal myocytes increases with age and in a denervation-induced muscle atrophy mouse model. Interestingly, Angptl2-deficient mice in the atrophy model showed relatively decreased inflammation and ROS accumulation and increased satellite cell activity. In sarcopenia development, both inflammation and excess ROS accumulation damage skeletal myocytes and inactivate satellite cells, accelerating muscle mass loss (14). Taken together, these findings suggest that ANGPTL2 contributes to sarcopenia development by accelerating inflammation and ROS accumulation in skeletal muscle and subsequently inactivating satellite cells.
Large amounts of ROS released from senescent skeletal myocytes may enhance oxidative damage to skeletal muscle (33). Excessive ROS accumulation with age is reportedly due to decreased activity and production of antioxidant enzymes (34). Here, using young mice, we observed that global ROS levels did not significantly change in Angptl2 Flox/Flox ;MCK-Cre mice compared with Angptl2 Flox/Flox mice, but slightly decreased ROS levels were observed in some low-molecular-weight proteins (Fig. 2d). However, others have reported that global ROS levels induced by denervation significantly decrease in Angptl2 Flox/Flox ;MCK-Cre mice related to Angptl2 Flox/Flox mice (35). Consistent with these results, we found that Angptl2 knockdown in differentiated C2C12 cells resulted in low ROS levels (Fig. 2i). Accordingly, catalase levels increased in both normal and denervated Angptl2 Flox/Flox ;MCK-Cre mice Figure 1. ANGPTL2 levels increase in skeletal muscle of aging mice. a, relative transcript levels of cellular senescence-associated (p16, p19, p21, and p57) and pro-inflammatory (Il-1␤ and Il-6) genes in musculus gastrocnemius and musculus soleus of adult (8-month-old) and aging (18-month-old) female wildtype mice (n ϭ 4 per group). b, absolute muscle mass and body weight as well as tibia length normalized muscle mass in adult and aging mice (n ϭ 7-10 per group). c, representative Western blot of 4-HNE-adducted proteins, a product of oxidative stress, in musculus soleus of adult and aging mice. Asterisks indicate increased levels of 4-HNE-adducted proteins in aging mice. d-f, relative expression of genes encoding antioxidant enzymes (catalase, Sod1, Sod2, and Gpx1) (d) or Cd34, Pax3, and Pax7 (e), or Angptl2 (f) transcripts in musculus gastrocnemius and musculus soleus of adult and aging mice (n ϭ 4 per group). g, representative Western blot and the quantifications of ANGPTL2 and PAX7 proteins in musculus gastrocnemius and musculus soleus of adult and aging mice. h, representative Western blot of ANGPTL2 in SMC-rich or stromal cells-rich fractions isolated from musculus gastrocnemius of adult and aging mice. Myosin light chain (MYL) serves as a skeletal myocyte marker. Relative mRNA expression was normalized to 18S mRNA (a, d, e, and f). Hsc70 and CBB staining serves as an internal loading control (c, g, and h). Values in adult mice were set to 1 (a and d-g). All data are presented as means Ϯ S. D. (a, b, and d-

ANGPTL2 accelerates skeletal muscle atrophy
as seen in Angptl2-knockdown differentiated C2C12 cells (Figs. 2, e and j and 5c). Overall, these results indicate that ANGPTL2-induced ROS accumulation may require catalase down-regulation.
Peroxisome proliferator-activated receptors (PPARs) reportedly play important roles in activating transcription of genes encoding antioxidant enzymes (36). Recent studies report that PPAR␣ activates catalase expression and that PPAR␣ expression decreases with age in tissues like skin and heart (37,38). Moreover, our recent study showed that in cardiomyocytes, excess ANGPTL2 signaling down-regulates PPAR␣ expression, whereas ANGPTL2 suppression up-regulates it (19). Taken together with findings reported here, we propose that excess ANGPTL2 signaling in aging skeletal ANGPTL2 accelerates skeletal muscle atrophy muscle may enhance ROS accumulation by decreasing PPAR␣-mediated catalase expression.
Here, we also report that Angptl2 loss in skeletal muscle decreases expression of genes associated with inflammation and cellular senescence. We previously reported that ANGPTL2 promotes chronic tissue inflammation by activating the integrin ␣5␤1/nuclear factor-B (NF-B) pathway and through p38 MAPK activity (22,39,40). Therefore, we hypothesize that increased pro-inflammatory gene expression in skeletal muscle downstream of ANGPTL2 could be due to activation of these two pro-inflammatory pathways. Because inflammation and ROS induce cellular senescence (4,5), ANGPTL2 may accelerate muscle cell senescence by promoting both. As noted above, ANGPTL2 is an SASP factor, and its expression increases in senescent cells (20,21). Overall, up-regulated ANGPTL2 signaling in skeletal muscle cell may underlie inflammation, ROS accumulation, and cellular senescence.
In aging muscle, satellite cell self-renewal activity is reduced, and the number of quiescent satellite cells decreases (41). Moreover, differentiation of activated satellite cells and myotube formation are impaired in aging muscles (42). Interestingly, in young mice, ANGPTL2 suppression in skeletal myocytes increases the number of activated satellite cells without affecting quiescent satellite cell population, suggesting that ANGPTL2 deficiency in skeletal myocytes does not impair satellite cell self-renewal capacity. We also showed that decreased expression of several genes associated with both satellite cell activation and increased inflammation/ROS accumulation in a denervation-induced muscle atrophy mouse model is ameliorated by Angptl2 knockout. Inflammation and ROS block activity of satellite cell precursors of skeletal muscle cells (14), suggesting that at least ANGPTL2 antagonizes satellite cell development via these mechanisms. Further studies are necessary to investigate whether ANGPTL2 directly modulates satellite cell function or whether suppression of ANGPTL2 production from skeletal myocytes could prevent or ameliorate sarcopenia development.
Activated satellite cells reportedly proliferate, differentiate into myocytes, and fuse in muscle fibers, increasing muscle mass (43). Here, we showed that exercise-induced ANGPTL2 suppression decreases inflammation and ROS accumulation and facilitates satellite cell activation. Taken together, these findings suggest that satellite cells activated by exercise-in-duced ANGPTL2 suppression in skeletal myocytes could generate muscle fibers and that their presence could present loss of muscle mass.
Exercise training, including running and walking, counteracts development of heart failure and sarcopenia in humans (15)(16)(17). We recently observed decreased ANGPTL2 expression in mouse heart tissues after exercise training through exercise-induced, cardiac miR-222-mediated ANGPTL2 suppression (19). We also found that inactivation of heart-derived autocrine/paracrine ANGPTL2 signaling protected mice from heart failure development (19). Interestingly, this study shows that exercise training also suppresses ANGPTL2 expression in skeletal muscle and that ANGPTL2 suppression antagonizes muscle fiber loss induced by denervation. It is noteworthy that exercise-induced ANGPTL2 suppression is a potential mechanism underlying exercise-associated prevention of sarcopenia development. Further studies are needed to determine how exercise training decreases ANGPTL2 expression in skeletal muscle on a mechanistic level.
We previously reported that circulating levels of ANGPTL2 increase with age in the general Japanese population and in mice (23). Interestingly, we found that in mice the age-dependent increases in serum ANGPTL2 concentration are suppressed by skeletal myocyte-specific ANGPTL2 deletion (Fig.  S3b), suggesting that increased ANGPTL2 production from myocytes contributes in part to age-dependent increases in circulating levels of this factor.
In summary, this is the first study to report that increased ANGPTL2 produced from skeletal muscle may be a novel factor involved in promoting loss of muscular volume, enhancing inflammation and ROS accumulation, and suppressing satellite cell activity (Fig. 7, left panel). We also propose that exercise-induced ANGPTL2 suppression could reduce inflammation and ROS accumulation, facilitating satellite cell activation required to maintain muscle mass (Fig. 7, right panel).

ANGPTL2 accelerates skeletal muscle atrophy
previously (19). Mice were fed a normal diet and water ad libitum, bred in a mouse house with automatically controlled lighting (12 h on, 12 h off), and maintained at a stable temperature of 23°C. All experimental procedures were approved by the Kumamoto University Ethics Review Committee for Animal Experimentation.

Mouse denervation-induced muscle atrophy model
Twelve-week-old female Angptl2 Flox/Flox ;MCK-Cre mice were anesthetized by intraperitoneal injection with sodium pentobarbital. The sciatic nerve of the left hindlimb was excised ϳ0.5-1 cm, whereas the sciatic nerve of the contralateral hindlimb was sham-operated by exposure without excision. At 3, 7, and 14 days after denervation, mice were sacrificed for analysis.

Exercise training
Exercise was performed as described previously (19). Briefly, 12-week-old male mice were exposed to a treadmill chamber with free movement for environmental adaptation for 30 min before the exercise. Mice were then trained using the following protocol: 5 m/min for 5 min, 10 m/min for 5 min, 15 m/min for 5 min, and 20 m/min for 60 min. These mice were sacrificed immediately or 3 h after exercise. A different group of endurance-trained mice were trained for 2 weeks (5 days/week) and were sacrificed 3 h after the last run.

Isolation of skeletal muscle myofibers and non-myofibers
Isolation followed a previously described protocol (44). Briefly, as shown in Fig. S2a, gastrocnemius muscle was dissected and incubated in collagenase solution (L-15 medium (1601301, Gibco TM Life Technologies, Inc.) containing 500 units/ml collagenase type ⌱ (CLS1, Worthington)) at 37°C for 2 h. Muscle was transferred to pre-warmed PBS and then flushed with PBS using a pipette under a microscope until myofibers were isolated. The entire solution was then collected and passed in turn through 100-and 40-m mesh filters. The filtrate was collected into a new Falcon tube and centrifuged at 3000 rpm for 5 min to collect non-myofibers. The 100-m mesh filter was flushed with pre-warmed PBS from the underside, and the flushed fluid was transferred to a new Falcon tube and centrifuged as above to collect myofibers. The supernatant was discarded, and the pellet was subjected to RNA extraction or to Western analysis.

ANGPTL2 ELISA
A human ANGPTL2 assay kit-IBL (27745; Immuno-Biological Laboratories, Gunma, Japan) was used to measure ANGPTL2 concentration in supernatants or in mouse serum in accordance with the manufacturer's instructions. Briefly, supernatants were diluted 10-fold with EIA buffer, and 100 l of the sample was placed into wells of a tissue culture plate. Samples were incubated 60 min at 37°C, washed four times with the washing buffer provided, and then treated with labeled antibody solution and incubated another 30 min at 4°C . Samples were then washed five times and then treated with 3,3Ј,5,Ј-tetramethylbenzidine (TMB) solution for 30 min at room temperature protected from light. After addition of stop solution, plates were then analyzed for absorbance at A 450 nm using an iMark TM microplate reader (168-1130 JA, Bio-Rad).

Catalase activity assay
Catalase activity was measured using a catalase activity assay kit (ab83464, Abcam, Cambridge, UK) according to the manufacturer's instructions. Briefly, C2C12 cells or skeletal muscle tissues were homogenized in assay buffer and purified. Standards, the positive control, the sample, or the sample high control were added to 96-well plate in volumes described in the manufacturer's instructions prior to addition of the reagent. Absorbance at A 595 nm was measured using an iMark TM microplate reader (168-1130 JA, Bio-Rad), and catalase activity was calculated using formulas supplied by the manufacturer (Abcam, Cambridge, UK).

ROS detection
C2C12 cellular ROS was detected using CM-H2DCFDA reagent (General Oxidative Stress Indicator) (C6827, Invitrogen) based on the manufacturer's instructions. Briefly, cells were seeded in a 96-well microplate and incubated for 30 min at  1 (a and c). All data are presented as means Ϯ S. D. (a and b) or means Ϯ S.E. (c); statistical significance was determined by Student's t test. *, p Ͻ 0.05; **, p Ͻ 0.01.

ANGPTL2 accelerates skeletal muscle atrophy
37°C with 10 M CM-H2DCFDA and then washed twice with PBS. Cellular ROS levels were then detected at an excitation/ emission of 485/515 nm using a Fluoroskan Ascent Microplate Luminometer (Thermo Fisher Scientific Inc., Carlsbad, CA). Data were analyzed using Ascent software (Version 2.6). Skeletal muscular ROS levels were assessed by examining the 4-HNE-adducted protein levels in skeletal muscle samples (see under "Western blotting").

SPiDER-␤gal staining
SPiDER-␤gal reagent (SG02, DOJINDO, Kumamoto, Japan) was used for cellular ␤gal staining based on the manufacturer's instructions. Briefly, cells were seeded on 96-well microplates or chamber slides (SCS-002, Matsunami, Osaka, Japan) for differentiation. After Angptl2 knockdown, 1mol/liter SPiDER-␤gal working solution was added and incubated for 15 min at 37°C protected from light. After 2 washes with PBS, cells were evaluated using a Fluoroskan Ascent Microplate Luminometer (Thermo Fisher Scientific Inc.) or images were obtained using a fluorescence microscope (model BZ-9000; Keyence, Osaka, Japan).

Cellular mechanical stretch
C2C12 cells were seeded on BIOFLEXPLATE COLLAGEN ⌱-BF 3001C (Flexcell International Corp., Burlington, NC) plates. After differentiation, cells were subjected to 5, 10, or 15% elongation with 1 Hz sine wave cyclic stretch for 15 or 30 min. Control cells were not subjected to stretch. Cells were then harvested and immediately analyzed.

Histological staining
For routine hematoxylin and eosin (HE) staining, skeletal muscle was dissected, fixed in 4% formalin for Ͼ12 h at room temperature, then embedded in paraffin, and cut into 5-mthick sections. Images were obtained using a fluorescence microscope (model BZ-9000; Keyence, Osaka, Japan). The area   D. (a-c, e, and f, left) or means Ϯ S.E. (d and f, right); statistical significance was determined by Student's t test (a and b) or one-way ANOVA (c and d-f). *, p Ͻ 0.05; **, p Ͻ 0.01; †, p Ͻ 0.001.

ANGPTL2 accelerates skeletal muscle atrophy
of each cellular cross-section was analyzed using BZ-X analyzer software (Keyence, Osaka, Japan).

RT-PCR
Total RNA was isolated from C2C12 cells or skeletal muscle using an RNeasy mini kit (Qiagen, Valencia, CA). mRNA was converted to cDNA using a Prime Script RT reagent kit (Takara Bio Inc., Shiga, Japan). PCRs were performed in a Thermal Cycler Dice Real-Time System TP870 (Takara Bio Inc., Shiga, Japan) using SYBR Premix EX Taq (Takara Bio Inc., Shiga, Japan) according to the manufacturer's instructions. Relative gene expression was determined using the standard curve method, and fold-changes of targeted genes were normalized to 18S mRNA. Primer sequences used are shown in Table S1.

Statistical analyses
All data are represented as the means Ϯ S.D. or means Ϯ S.E. of the mean. Statistical significance of two group comparisons of variables was determined using Student's t test, and multiple comparisons were assessed by one-or two-way ANOVA. p Ͻ 0.05 was considered statistically significant.  Left, ANGPTL2 expression in skeletal myocytes increases with age. Skeletal myocyte-derived ANGPTL2 promotes inflammation and facilitates ROS accumulation by decreasing catalase expression in skeletal muscle. Increased ANGPTL2 and associated inflammation and ROS accumulation impair satellite cell activity in skeletal muscle, leading to atrophy. Right, exercise training decreases ANGPTL2 expression in skeletal muscle as it suppresses inflammation and ROS accumulation. These activities facilitate satellite cell activation that contribute to maintenance of muscle mass. Thus, exercise training-induced ANGPTL2 down-regulation represents a potential mechanism underlying exercise-induced protection from muscle atrophy.